CompassCare CEO Jim Harden believes that the FDA’s latest decision opens the door to serial malpractice.
The FDA has taken another step to deregulate chemical abortion pills by modifying their Risk Mitigation and Evaluation Strategy for Mifepristone. Medical ethicist sounds the alarm that this will lead to continued malpractice.
Earlier this week, the FDA published a new set of rules that would permit certified pharmacies to fulfill chemical abortion drug prescriptions. Of course, these vary by state, since some have restrictive laws in place. It is expected that the FDA’s decision will increase the number of chemical abortions, which currently represents 54 percent of all abortion.
However, Jim Harden, CEO of CompassCare, a pro-life medical network, believes that this move by the FDA will continue the “serial malpractice” Of the chemical abortion industry.
Chemical abortion drugs are often assigned to women before a physician diagnoses their pregnancy or identifies any contraindications. Circumventing proper diagnosis of the patient is unethical and puts women’s lives at risk—chemical abortion leaves a woman 500% more likely to end up in the ER with serious complications than even surgical abortion. “This is a purely political move at the expense of women’s health,” Rev. Harden stated in a news release earlier this week. “RU-486 will go down in history as the chemical coat hanger.”
Harden continued, “Now more than ever, pro-life pregnancy centers need to serve these women before they go online and have dangerous chemical abortion drugs mailed to their homes. And therefore, pro-life pregnancy centers are being targeted. We are providing women with informed consent and options other than abortion. This harms the abortion empire’s bottom line.”
Harden (or CompassCare’s Director of Community Relations, Daniel Tomlinson) joins us now to discuss the FDA’s latest move further.
Q&A:
- Why is chemical abortion so heavily utilized right now? Is it mainly due to its inexpensiveness or the lack of a need to visit a physician?
- Can you break down what kind of risk chemical abortion is to women, especially those that don’t consult a physician?
- Why do you think the FDA gave this approval to pharmacies? Is this a reaction to the Supreme Court overturning Roe vs. Wade last year? Or something else?
- How can CompassCare help these women in their time of need, before they take a chance on chemical abortion?
- CompassCare is still reeling from a firebombing attack that took place in Buffalo last year, as the suspects have yet to be arrested. Any update on this? Is there someone looking further into the matter?
- For those that are interested in supporting CompassCare and learning more about the services they provide, where can they go?
You can find out more information on our community page.
About Rev. James Harden…
Rev. James R. Harden, M.Div. is the CEO of CompassCare Pregnancy Services and lives outside of Rochester, NY with his wife and ten children. Jim pioneered the first measurable and repeatable medical model in the pregnancy center movement, helping hundreds of centers nationwide become more effective at reaching more women and saving more babies from abortion. He has written extensively on medical ethics, executive leadership, and pro-life strategy.
CONTACT: Gerald McGlothlin at: jerry.specialguests@gmail.com or 919-437-0001.
